Transcend Capital Advisors LLC Acquires 3,757 Shares of Danaher Co. (NYSE:DHR)

Transcend Capital Advisors LLC raised its stake in Danaher Co. (NYSE:DHR) by 36.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,971 shares of the conglomerate’s stock after buying an additional 3,757 shares during the period. Transcend Capital Advisors LLC’s holdings in Danaher were worth $3,491,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Norges Bank purchased a new stake in shares of Danaher in the fourth quarter worth $1,752,382,000. Vanguard Group Inc. grew its holdings in shares of Danaher by 7.4% during the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after acquiring an additional 4,163,657 shares during the period. Wellington Management Group LLP grew its holdings in shares of Danaher by 12.0% during the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock worth $6,460,966,000 after acquiring an additional 2,998,161 shares during the period. Swedbank AB bought a new stake in shares of Danaher in the 1st quarter worth approximately $676,545,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its position in shares of Danaher by 214.4% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,073,661 shares of the conglomerate’s stock worth $711,051,000 after purchasing an additional 2,096,038 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have issued reports on DHR shares. Royal Bank of Canada increased their price target on Danaher from $297.00 to $300.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Evercore ISI lowered their price target on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. TD Cowen raised their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Jefferies Financial Group assumed coverage on shares of Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 target price on the stock. Finally, Barclays lifted their price objective on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a report on Wednesday, July 24th. Six equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, Danaher has a consensus rating of “Moderate Buy” and a consensus price target of $276.88.

Insider Transactions at Danaher

In other news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the transaction, the chief financial officer now directly owns 29,407 shares in the company, valued at $8,229,254.88. The disclosure for this sale can be found here. Insiders sold a total of 113,174 shares of company stock worth $29,775,644 over the last ninety days. 11.10% of the stock is currently owned by corporate insiders.

Danaher Stock Down 1.4 %

Shares of NYSE:DHR traded down $4.01 during trading hours on Friday, reaching $276.75. The stock had a trading volume of 3,108,808 shares, compared to its average volume of 3,183,765. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The firm’s 50 day moving average is $256.29 and its 200-day moving average is $250.94. The stock has a market capitalization of $199.87 billion, a price-to-earnings ratio of 46.91, a P/E/G ratio of 4.62 and a beta of 0.83. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter last year, the business earned $2.05 earnings per share. The business’s revenue for the quarter was down 2.9% compared to the same quarter last year. Research analysts predict that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, July 26th. Stockholders of record on Friday, June 28th were issued a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.